Steroid Withdrawal Based on Lymphocyte Sensitivity to Endogenous Steroid in Renal Transplant Recipients
Open Access
- 1 January 2011
- journal article
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 34 (10) , 1578-1583
Abstract
Though steroid withdrawal is done in many renal transplant recipients, some patients must restart steroids. Little report has investigated steroid withdrawal under pharmacodynamic monitoring. We assessed lymphocyte sensitivity to endogenous cortisol as a biomarker for determining the safety of steroid withdrawal in renal transplant patients, as we hypothesized that patients hyposensitive to cortisol could not be sufficiently immunosuppressed by their intrinsic cortisol as a substitute for the reduced or withdrawn steroid. Lymphocyte sensitivity to cortisol was examined in 30 long stable renal transplant recipients. Lymphocyte sensitivity to cortisol and its relationship with the clinical outcome after steroid reduction and withdrawal was investigated. The lymphocyte sensitivities to cortisol were estimated as IC50 of lymphocyte blastogenesis. The lymphocyte proliferation rate for concentration of serum cortisol compared between incident and non-incident groups. Serum creatinine levels (S-Cr) increased in a significantly higher number of patients hyposensitive to cortisol (IC50≧10000 ng/ml) than in normally sensitive patients (IC50<10000 ng/ml). The incidences of steroid withdrawal syndrome and necessity for increasing steroid dose or restarting steroid administration were also higher in the patients hyposensitive to cortisol. The patients in whom the lymphocyte proliferation rate was less than 60% did not show increase in S-Cr, experience steroid withdrawal symptoms, or require an increase in the steroid dose or restart of steroid administration. The patients who have the normal IC50 values of cortisol, can withdraw steroid more safely. The lymphocyte sensitivity to cortisol may be a useful biomarker for selecting patients who can sustain steroid withdrawal.Keywords
This publication has 14 references indexed in Scilit:
- Cyclosporine Withdrawal Improves Long-Term Graft Survival in Renal TransplantationTransplantation, 2009
- A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, Low-Dose Corticosteroid TherapyAnnals of Surgery, 2008
- A Randomized, Multicenter Study of Steroid Avoidance, Early Steroid Withdrawal or Standard Steroid Therapy in Kidney Transplant RecipientsAmerican Journal of Transplantation, 2008
- Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipientsInternational Immunopharmacology, 2006
- Steroid Sparing in Kidney TransplantationClinical Journal of the American Society of Nephrology, 2006
- Steroid Withdrawal in Renal Transplant Patients on Triple Therapy with a Calcineurin Inhibitor and Mycophenolate Mofetil: A Meta-analysis of Randomized, Controlled TrialsTransplantation, 2004
- REDUCTION OF THE OCCURRENCE OF ACUTE CELLULAR REJECTION AMONG RENAL ALLOGRAFT RECIPIENTS TREATED WITH BASILIXIMAB, A CHIMERIC ANTI-INTERLEUKIN-2-RECEPTOR MONOCLONAL ANTIBODY1,2Transplantation, 1999
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- IN VITRO SENSITIVITY TO PREDNISOLONE MAY PREDICT KIDNEY REJECTION AFTER STEROID WITHDRAWALTransplantation, 1996
- SYSTEMIC CHIMERISM IN SEX-MISMATCHED LIVER TRANSPLANT RECIPIENTS DETECTED BY FLUORESCENCE IN SITU HYBRIDIZATIONTransplantation, 1994